REDWOOD CITY, Calif., Aug. 14, 2026
asper Therapeutics, Inc. reported continued progress in its immune-mediated disease portfolio following the completion of its acquisition of Kira Pharmaceuticals in July 2026 and a concurrent $132 million private placement financing. The combination creates a clinical-stage biotechnology company with a broader portfolio of potential therapies targeting immunologically driven disorders. The transaction brings KP-104 (vensobafusp alfa), briquilimab, and KP-701 into the combined company’s development portfolio and provides additional resources to advance multiple programs. Jasper expects the financing to support planned operations through the second half of 2028, allowing the company to focus on clinical development, regulatory preparation and advancement of its lead assets across complement-mediated, transplant and autoantibody-driven diseases.
Kira Acquisition Expands Jasper’s Clinical Pipeline
The Kira Pharmaceuticals acquisition, completed on July 16, represents the central development in Jasper’s latest corporate update. The all-stock transaction combines Jasper’s existing programs with Kira’s complement-focused portfolio, creating a broader pipeline addressing several areas of significant unmet medical need. The leading program is KP-104 (vensobafusp alfa), a bifunctional biologic designed to inhibit both the alternative and terminal pathways of the complement cascade. KP-104 is considered Phase 2/3-ready and is currently being evaluated in a Phase 2 basket trial covering rare renal indications. Jasper expects interim Stage 1 data in the fourth quarter of 2026. The company also plans an end-of-Phase 2 meeting with the FDA regarding development of KP-104 in paroxysmal nocturnal hemoglobinuria (PNH), with further development plans expected during the first half of 2027.
Briquilimab and KP-701 Advance Toward Clinical Milestones
The combined company is also advancing briquilimab, a late-stage anti-KIT antibody being developed across transplant and immune-mediated indications. Jasper is using positive long-term data generated in severe combined immunodeficiency (SCID) to support preparations for a potential pre-BLA meeting with the FDA, with additional development plans expected in the first quarter of 2027. Another key asset is KP-701, a novel dual-acting anti-CD79B×CD32B monoclonal antibody designed for autoantibody-mediated disorders. Jasper expects to submit a clinical trial application and/or IND in the first quarter of 2027, potentially enabling first-in-human Phase 1 evaluation. Together, these programs broaden the company’s development strategy beyond complement inhibition and provide multiple potential clinical catalysts over the coming quarters.
Advertisement
$132 Million Financing Supports Development Strategy
The acquisition was completed alongside a $132 million financing, providing significant capital to support development of the combined pipeline. Jasper’s corporate strategy now centers on advancing KP-104, progressing briquilimab toward a potential BLA, and preparing KP-701 for first-in-human studies. As of June 30, 2026, Jasper reported $7.3 million in cash and cash equivalents, before the subsequent financing associated with the Kira transaction. Second-quarter research and development expenses were $5.1 million, while general and administrative expenses were $4.1 million. The company reported a net loss of $2.8 million, or $0.10 per share, for the quarter. With the newly expanded pipeline and financing in place, Jasper’s near-term focus is on generating KP-104 Phase 2 data, advancing regulatory preparations for briquilimab and moving KP-701 toward clinical development, establishing a series of important milestones for the combined company through 2027.
Source: Jasper Therapeutics press relese
